COVID-19 and Lung Cancer: What We Know and Don’t Know
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
A small study on patients with metastatic melanoma who were treated with autologous vaccines in a phase 2 clinical trial suggests that soluble PD-1 may have potential as a prognostic biomarker.